This inventor holds 16 USPTO granted patents and 1 published patent application, plus 2 CIPO patents, primarily in Biopharmaceutical Proteins. Top assignee: Novagen Holding Corporation. Active years: 2009-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Beijing, CN (2016 - 2021)
- Vancouver, CA (2009 - 2022)
Company Filing History:
Years Active: 2009-2022
Areas of Expertise:
Title: Innovations of Longbin Liu in Biotechnology
Introduction
Longbin Liu is a prominent inventor based in Vancouver, Canada, known for his significant contributions to the field of biotechnology. With a total of 16 patents to his name, Liu has made remarkable advancements, particularly in the development of recombinant proteins that enhance therapeutic efficacy.
Latest Patents
Among his latest patents is the invention of recombinant human EPO-FC fusion proteins with a prolonged half-life and enhanced erythropoietic activity in vivo. This innovative fusion protein comprises a human erythropoietin peptide portion linked to an immunoglobulin peptide portion. The fusion protein demonstrates a half-life in vivo that is at least three times longer than that of naturally occurring or recombinant native human erythropoietin. Additionally, it exhibits enhanced erythropoietic bioactivity compared to its native counterpart. The invention also includes nucleic acid and amino acid sequences encoding the fusion protein, as well as methods for producing it and pharmaceutical compositions that utilize the fusion protein for therapeutic purposes.
Another notable patent involves fusion proteins that have a mutated immunoglobulin hinge region. This fusion protein features a non-immunoglobulin polypeptide with a cysteine residue and an immunoglobulin component with a mutated hinge region. The design prevents the formation of disulfide bonds, enhancing the stability and functionality of the protein.
Career Highlights
Longbin Liu is currently associated with Novagen Holding Corporation, where he continues to innovate and develop groundbreaking biotechnological solutions. His work has significantly impacted the field, particularly in the area of therapeutic proteins.
Collaborations
Liu has collaborated with notable colleagues, including Haitao Wang and Rui Zhang, contributing to various research projects and patent developments.
Conclusion
Longbin Liu's innovative work in biotechnology, particularly in the development of recombinant proteins, showcases his expertise and commitment to advancing medical therapies. His contributions continue to influence the field and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile